Compass Pathways is nearing an inflection point, with solid Phase III data and government support pointing towards a likely ...
Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed ...
Investor's Business Daily on MSN
Here's why this psychedelics stock just took a trip to a two-year high
Compass Pathways stock jumped Wednesday after the psychedelics-tied biotech significantly boosted its cash holdings.
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based ...
Shares of Compass Pathways (NASDAQ:CMPS) climbed nearly 8% in premarket trading on Wednesday after the company reported first ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results ...
COMPASS Pathways Plc CMPS reported first-quarter earnings on Wednesday before the market open. Here’s a rundown of the report ...
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...
Shares of the biotechnology company rocketed more than 50% this morning and were still higher by 41.2% at noon ET. Compass is ...
Compass Pathways is set to start its biggest clinical trial yet by the end of this year. It will study whether synthetic psilocybin can help people with treatment-resistant depression. Compass' new ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results